image15
Artistic interpretation of ocular anatomy. Courtesy of Project VISIONS (www.the-visions.com)

Therapeutics for Age-related Macular Degeneration (AMD)

Visgenx is developing therapeutics to protect against the loss of sight  from retinal disorders.  Our programs are based on increasing the expression of a gene known as ELOVL2  which may regulate aging in cells critical for vision.

THERAPEUTIC FOCUS

Age-related Macular Degeneration / Geographic Atrophy


DEVELOPMENT STRATEGY

Our fast-to-market approach is based on epigenetic rescue of ELOVL2 using decitabine.  Our longer term goal is ELOVL2 gene therapy.